Highly concentrated dosage forms of HGH fusion proteins
A high-concentration hGH-hyFc dosage form with Poloxamer 188 and Polysorbate 80 addresses the challenges of daily injections by reducing protein aggregation and enhancing storage stability, facilitating less frequent administration and improved patient compliance.
Patent Information
- Application Number
- JP2024531548
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-26
- Filing Date
- 2022-10-19
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current growth hormone (hGH) preparations, particularly for pediatric patients, require daily injections, leading to inconvenience, mental stress, and non-adherence issues, and there is a need for a high-concentration dosage form that minimizes protein aggregation and maintains storage stability.
A high-concentration liquid pharmaceutical dosage form of hGH fusion protein (hGH-hyFc) is developed, containing Poloxamer 188 and Polysorbate 80 as surfactants, along with excipients like histidine, arginine, glutamic acid, and sodium chloride, to prevent protein aggregation and enhance storage stability.
The dosage form significantly reduces protein aggregation and maintains stability for up to 6 months under refrigeration, allowing for less frequent administration and improved patient compliance.
Smart Images

Figure 2024541558000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a high-concentration dosage form of hGH (human growth hormone) fusion protein, and more particularly to a high-concentration dosage form of hGH fusion protein in which aggregation reaction is significantly reduced even in a high-concentration dosage form of hGH fused with an immunoglobulin Fc polypeptide (hereinafter referred to as "hyFc") by containing poloxamer 188 and polysorbate 80. [Background technology]
[0002] Growth hormone is a polypeptide consisting of 191 amino acids, and is secreted from the anterior pituitary gland. It is involved in cell growth and regeneration by binding to growth hormone receptors and expressing IGF-1 (Insulin-like Growth Factor-1). It is known that growth hormone is produced in the pituitary gland in normal human bodies, and production increases until puberty, then gradually decreases as we age.
[0003] Representative symptoms of growth hormone deficiency include adult growth hormone deficiency (AGHD) and pediatric growth hormone deficiency (PGHD). Adult growth hormone deficiency occurs when the patient's pituitary gland is damaged by radiation or surgery during the treatment of brain tumors or cerebral hemorrhage, or it occurs idiopathically. When growth hormone is not secreted properly, symptoms such as weight loss, decreased bone mineral density, increased fat, decreased HDL, increased LDL, and decreased muscle strength appear, resulting in a decreased quality of life. Adult growth hormone deficiency patients have serum IGF-1 concentrations below -2 standard deviation score (SDS) or within 2.5 percentile (SDS) compared to normal people of the same age group. The response value of growth hormone in the blood can be measured through stimulation tests such as insulin tolerance test (ITT), arginine loading test (Growth hormone-releasing hormone + Arginine, GHRH + ARG), glucagon test, L-DOPA test, and clonidine test. The maximum value of growth hormone (peak GH) is reached when the body mass index (BMI) is 25 kg / m 2 11.0 μg / L or less for patients with a body mass index of 25 to 30 kg / m 2 Patients with a serum cholesterol level of 8.0 μg / L or lower or a body mass index of 30 kg / m 2In patients with excess levels, those with levels below 4.0 μg / L are diagnosed as having growth hormone deficiency (Guidelines for Use of Growth Hormone in Clinical Practice, Endocr. Pract. 2009;15(Suppl 2)). Childhood growth hormone deficiency occurs when there is damage to the pituitary gland or developmental disorder. When there is a defect in the secretion of growth hormone, short stature appears, with height falling in the bottom 3% of the growth curve for the same age or growth of less than 5 cm per year, and symptoms such as hypoglycemia, decreased physical strength, depression, and mental immaturity may also appear. A diagnosis of childhood growth hormone deficiency can be made if the height of a child is 3 standard deviations (SDs) or more lower than the mean, 1.5 standard deviations or more lower than the mean height of the parents, 2 standard deviations or more lower than the mean height, or 1 standard deviation or more lower than the growth rate of the child for at least one year, or if the height is 0.5 SDs or more lower than the growth rate of the child for at least two years, or if symptoms of short stature do not appear but the height is less than 2 SDs for at least one year or remains 1.5 SDs for at least two years (Consensus guideline for the diagnosis and treatment of GH deficiency in childhood and adolescence:summary statement of the GH Research Society.GH Research Society,J.Clin.Endocrinol.Metab.,2000 Nov;85(11):3990-3).
[0004] Growth hormone deficiency is mainly treated with growth hormone, but when growth hormone treatment first began in the 1950s, growth hormone was extracted from the pituitary gland of human cadavers, and the amount of growth hormone extracted from one person was very small, so the supply was very limited and expensive. As recombinant gene technology developed, growth hormone synthesized in Escherichia coli was released (Somatropin, 1981, Genentech, USA). Recombinant growth hormone treatments currently available in the USA include Genotropin by Pfizer, Humatrope by Eli Lilly, Nutropin by Genentech, and Norditropin by Novo Nordisk.
[0005] Currently, growth hormone preparations are administered daily, which is inconvenient for pediatric patients, as they must be injected every day for a long period of treatment of 3 to 4 years. It is also known that the psychological stress caused by injections reduces the quality of life of patients. In addition, there are frequent cases of patients unintentionally not receiving their injections, which is the biggest factor hindering the effectiveness of treatment. It is also known that the number of non-compliance cases increases significantly with the number of years of treatment (Endocrine practice, 2008 Mar; 14(2): 143-54). It is known that about two-thirds of patients have poor adaptation due to non-compliance, which actually reduces their height growth rate (PloS one, 2011 Jan; 6(1): e16223).
[0006] Due to these problems, there have been steady attempts to develop sustained release growth hormone using various technologies: Ascendis Pharma using the Transcon PEG platform, OPKO / Pfizer fusing hGH with CTP, and Novo Nordisk fusing it with albumin to increase the half-life of hGH, allowing patients to administer growth hormone once a week instead of daily.
[0007] In this regard, the applicant has applied for and received a patent for the GX-H9 substance, which has low complement-dependent and antibody-dependent toxicity and improved durability of hGH by fusing hyFc, a combination of IgD and IgG4, to hGH (US Patent No. 8,529,899).Next, the applicant applied for a patent for a dosage method that allows GX-H9 to be administered once a week or once every two weeks (US Patent Publication No. 2021-0177945 and US Patent Publication No. 2019-0224281).
[0008] In the early stages of clinical trials, GX-H9 was formulated and supplied at a concentration of 30mg / ml. Later, as GX-H9 was administered once every two weeks, the GX-H9 dosage volume increased, creating a need for a higher concentration formulation.
[0009] Therefore, the inventors predicted the structural characteristics through sequence analysis of GX-H9, and noticed that hGH has many hydrophobic patches and the protein itself can form aggregates due to hydrophobic interactions, and that proteins adsorb to the gas / oil / solid surfaces in the DP (Drug Product) container to form a kind of protein film, and the patches formed when these are detached can form aggregates as insoluble particles. They made efforts to develop a dosage form that can prevent the formation of such aggregates, and confirmed that the formation of aggregates was significantly improved in a liquid dosage form to which polysorbate 80 and poloxamer 188 were added as surfactants, thereby completing the present invention. Summary of the Invention [Problem to be solved by the invention]
[0010] An object of the present invention is to provide a high concentration formulation of hGH-hyFc fusion protein which significantly reduces protein aggregation reaction and maintains storage stability when producing the high concentration formulation of hGH fusion protein. [Means for solving the problem]
[0011] To achieve the above object, the present invention provides a liquid pharmaceutical formulation comprising a human growth hormone (hGH) fusion protein, poloxamer 188 and polysorbate 80.
[0012] In the present invention, the hGH fusion protein is characterized in that it contains hGH and an immunoglobulin Fc polypeptide.
[0013] In the present invention, the hGH is characterized by having the amino acid sequence of SEQ ID NO:2.
[0014] In the present invention, the immunoglobulin Fc polypeptide is characterized in that it has the amino acid sequence of SEQ ID NO:3.
[0015] In the present invention, the hGH fusion protein is characterized in that it has the amino acid sequence of SEQ ID NO:1.
[0016] In the present invention, the dosage form is characterized in that it contains 30 mg / mL to 150 mg / mL of hGH fusion protein.
[0017] In the present invention, the dosage form is characterized in that it contains 0.01% to 0.2% (w / v) poloxamer 188.
[0018] In the present invention, the dosage form is characterized in that it contains 0.01% to 0.2% (w / v) polysorbate 80.
[0019] In the present invention, the dosage form is characterized in that it further comprises one or more excipients selected from the group consisting of histidine, arginine, glutamic acid, and sodium chloride (NaCl).
[0020] In the present invention, the dosage form is characterized in that it further contains a preservative.
[0021] In the present invention, the preservative is characterized in that it is one or more selected from the group consisting of m-cresol, phenol, and benzyl alcohol.
[0022] In the present invention, the preservative is characterized in that it is phenol at 1 mg / mL to 2 mg / mL.
[0023] In the present invention, the dosage form is characterized in that it contains 1 mM to 20 mM of histidine.
[0024] In the present invention, the dosage form is characterized in that it contains 40 mM to 70 mM arginine.
[0025] In the present invention, the dosage form is characterized in that it contains 40 mM to 70 mM glutamic acid.
[0026] In the present invention, the dosage form is characterized in that it contains 80 mM to 100 mM sodium chloride.
[0027] In the present invention, the dosage form is characterized in that it has a pH of 5.5 to 7.0.
[0028] In the present invention, the dosage form is characterized in that the pH is preferably 6.0 to 6.9, and more preferably 6.0 to 6.2.
[0029] In accordance with the present invention, the dosage form is characterized by forming less than 1.5% aggregates upon storage for six months under refrigeration.
[0030] In the present invention, the dosage form is characterized in that it is for subcutaneous or intramuscular administration.
[0031] In the present invention, the dosage form is characterized in that it is stored in a container selected from the group consisting of a bottle, a microtube, a bag, a vial, a cartridge, an injector, and a syringe. Effect of the Invention
[0032] When the present invention contains poloxamer 188 and polysorbate 80, it is possible to prepare a highly concentrated hGH fusion protein formulation with significantly reduced aggregation and improved storage stability. [Brief description of the drawings]
[0033] [Figure 1] FIG. 1 shows the results of appearance analysis (visual inspection for insoluble foreign matter) to evaluate the stability of various formulations of GX-H9 with or without polysorbate 80.
[0034] [Diagram 2] FIG. 2 shows the results of fine particle (insoluble fine particle) analysis to evaluate the formulation stability in the presence or absence of polysorbate 80 in various formulations of GX-H9.
[0035] [Diagram 3] FIG. 3 shows the results of SE-UPLC analysis to evaluate the formulation stability of various formulations of GX-H9 with and without polysorbate 80.
[0036] [Figure 4]FIG. 4 shows the results of RP-HPLC analysis to evaluate the stability of various formulations of GX-H9 with and without polysorbate 80.
[0037] [Diagram 5] FIG. 5 shows the results of appearance analysis (visual inspection for insoluble foreign matter) to evaluate the dosage form stability depending on the concentration of polysorbate 80 in the GX-H9 dosage form.
[0038] [Figure 6] FIG. 6 shows the results of fine particle analysis to evaluate the formulation stability depending on the concentration of polysorbate 80 in the GX-H9 formulation.
[0039] [Figure 7] FIG. 7 shows the results of purity (SE-UPLC, RP-HPLC) analysis to evaluate the formulation stability depending on the concentration of polysorbate 80 in the GX-H9 formulation.
[0040] [Figure 8] FIG. 8 shows the results of appearance analysis (visual inspection for insoluble foreign matter) to evaluate the stability of the formulation under various GX-H9 concentrations, polysorbate 80 concentrations, and preservative conditions.
[0041] [Figure 9a] FIG. 9a shows the results of purity (SE-UPLC, RP-HPLC) analysis to evaluate the formulation stability under various GX-H9 concentration conditions.
[0042] [Figure 9b] FIG. 9b shows the results of purity (SE-UPLC, RP-HPLC) analysis to evaluate the stability of the GX-H9 formulation under various polysorbate 80 concentrations.
[0043] [Figure 9c] FIG. 9c shows the results of purity (SE-UPLC, RP-HPLC) analysis to evaluate the stability of GX-H9 formulations treated with various preservatives. BEST MODE FOR CARRYING OUT THEINVENTION
[0044] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a skilled artisan in the art to which this invention belongs. Generally, the nomenclature used herein is one that is well known and commonly used in the art.
[0045] In the present invention, it was confirmed that when a high-concentration dosage form of GX-H9 was produced, the formation of aggregates was significantly reduced when both polysorbate 80 and poloxamer 188 were contained as surfactants.
[0046] Accordingly, the present invention in one aspect relates to a liquid pharmaceutical dosage form comprising an hGH fusion protein, Poloxamer 188 and Polysorbate 80.
[0047] In the present invention, the hGH fusion protein is characterized in that it contains hGH and an immunoglobulin Fc polypeptide.
[0048] The hGH fusion protein "GX-H9" used in the present invention refers to hGH-hyFc, a human growth hormone fusion protein produced by fusing human growth hormone (hGH) with hybrid Fc. The hGH fusion protein GX-H9 can be produced by the method disclosed in U.S. Patent No. 8,529,899.
[0049] In the present invention, the hGH is characterized by having the amino acid sequence of SEQ ID NO: 2, but is not limited thereto.
[0050] In the present invention, the immunoglobulin Fc polypeptide is characterized by having the amino acid sequence of SEQ ID NO:3, but is not limited thereto.
[0051] In the present invention, the hGH fusion protein is characterized by having the amino acid sequence of SEQ ID NO:1, but is not limited thereto.
[0052] In the present invention, the dosage form is characterized by containing 30 mg / mL to 150 mg / mL of hGH fusion protein, preferably 60 mg / mL to 120 mg / mL of GX-H9, but is not limited thereto. The dosage form may contain, for example, 30 mg / mL, 40 mg / mL, 50 mg / mL, 60 mg / mL, 70 mg / mL, 80 mg / mL, 90 mg / mL, 100 mg / mL, 110 mg / mL, 120 mg / mL, 130 mg / mL, 140 mg / mL, or 150 mg / mL of GX-H9.
[0053] In the present invention, the dosage form is characterized by containing 0.01% (w / v) to 0.2% (w / v) poloxamer 188, preferably 0.05% (w / v) to 0.15% (w / v), or 0.08% (w / v) to 0.12% (w / v), more preferably 0.10% (w / v) poloxamer 188, but is not limited thereto.
[0054] In the present invention, the dosage form is characterized by containing 0.01% (w / v) to 0.2% (w / v) polysorbate 80, preferably 0.05% (w / v) to 0.15% (w / v), or 0.05% (w / v) to 0.10% (w / v), and more preferably 0.07% (w / v) polysorbate 80, but is not limited thereto.
[0055] In the present invention, the dosage form is characterized in that the dosage form further comprises one or more excipients selected from the group consisting of histidine, arginine, glutamic acid, and sodium chloride (NaCl).
[0056] In the present invention, the dosage form is characterized in that it further contains a preservative.
[0057] In the present invention, the preservative is characterized by being at least one selected from the group consisting of m-cresol, phenol, and benzyl alcohol, but is not limited thereto.
[0058] In the present invention, the preservative is characterized by being 1 mg / mL to 2 mg / mL phenol, and is preferably characterized by being 1 mg / mL phenol, but is not limited thereto.
[0059] In the present invention, the dosage form is characterized by containing 1 mM to 20 mM histidine, preferably 5 mM to 15 mM, and more preferably 10 mM histidine, but is not limited thereto.
[0060] In the present invention, the dosage form is characterized by containing 40 mM to 70 mM arginine, preferably 50 mM to 60 mM, and more preferably 55 mM arginine, but is not limited thereto.
[0061] In the present invention, the dosage form is characterized by containing 40 mM to 70 mM glutamic acid, preferably 50 mM to 60 mM, and more preferably 55 mM glutamic acid, but is not limited thereto.
[0062] In the present invention, the dosage form is characterized by containing 80 mM to 100 mM sodium chloride, preferably 85 mM to 95 mM, and more preferably 90 mM sodium chloride, but is not limited thereto.
[0063] In the present invention, the dosage form is characterized by having a pH of 5.5 to 7.0, preferably a pH of 5.9 to 6.9, further preferably a pH of 6.0 to 6.5, even more preferably a pH of 6.0 to 6.2, and most preferably a pH of 6.1, but is not limited thereto.
[0064] In the present invention, the dosage form is characterized in that, when stored refrigerated, for example, at 2°C to 8°C, preferably 4°C to 6°C, for about 6 months, it forms less than 3.0%, preferably less than 2.0%, more preferably less than 1.5%, for example, 0 to 1.5%, of aggregates, but is not limited thereto.
[0065] In the present invention, the dosage form is characterized in that it is for subcutaneous or intramuscular administration.
[0066] In the present invention, the dosage form is characterized in that it is an injectable dosage form.
[0067] In the present invention, the dosage form is characterized in that it is stored in a container selected from the group consisting of a bottle, a microtube, a bag, a vial, a cartridge, an injector, and a syringe, but is not limited thereto.
[0068] For example, but not limited to, the dosage form may be characterized as being stored in a container selected from the group consisting of a glass vial, a glass cartridge, a plastic cartridge, a prefilled syringe, a pen injector, and an autoinjector.
[0069] The high-concentration GX-H9 pharmaceutical formulation of the present invention can be administered to adults or children with growth hormone deficiency. The high-concentration GX-H9 pharmaceutical formulation of the present invention can be administered to a subject in a variety of ways.
[0070] In the present invention, the subject may be a mammal, but is not limited thereto, and preferably, the subject may be a human.
[0071] For example, the dosage form can be administered parenterally, for example, subcutaneously or intramuscularly.
[0072] In the present invention, the term "pharmaceutical dosage form" refers to a preparation that contains GX-H9 in a form that allows the biological activity of GX-H9 to be effective and does not contain components that are toxic to the subject to which the dosage form is administered in amounts greater than acceptable doses.
[0073] A "stable" dosage form is one that substantially retains the physiological stability and / or chemical stability and / or biological activity of GX-H9 upon storage, storage and distribution. In one embodiment, the dosage form substantially retains its biological activity as well as its physiological and chemical stability upon storage. The storage period is generally selected based on the intended shelf life of the dosage form. Stability can be measured at a selected temperature for a selected time period. For example, in one embodiment, the liquid dosage form is stable at about 25°C for about 2 to 4 weeks, at least about 3 months, at least about 6 months, at least about 9 months, at least about 12 months, or at least about 18 months. As yet another example, the liquid dosage form is stable at about 5°C for about 2 to 4 weeks, at least about 3 months, at least about 6 months, at least about 9 months, at least about 12 months, at least about 18 months, at least about 24 months, at least about 30 months, or at least about 36 months.
[0074] Analytical techniques for measuring protein stability are extremely diverse, and references were made to previous literature [Peptide and Protein Drug Delivery, 247-301, Vincent Lee Ed., Marcel Dekker, Inc., New York, NY, Pubs. (1991) and Jones, A. Adv. Drug Delivery Rev. 10:29-90 (1993)].
[0075] The stability of liquid dosage forms can be assessed by assessment of dimer, multimer and / or aggregate formation (e.g., liquid chromatography such as size exclusion ultra-high performance liquid chromatography (SE-UPLC), size exclusion high performance liquid chromatography (SE-HPLC), reversed-phase ultra-high performance liquid chromatography (RP-UPLC), reversed-phase high performance liquid chromatography (RP-HPLC), etc.), matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS), analytical ultracentrifugation, light scattering (photon correlation spectroscopy, dynamic light scattering (DLS), static light scattering, multi-angle laser light scattering, etc.), and / or other techniques. by turbidity measurements using molecular scattering (MALLS), flow imaging microscopy, electronic impedance (Coulter) counters, light interception or other liquid particle measurement systems, and / or by visual inspection; by assessing charge heterogeneity using cation exchange chromatography (CEX), isoelectric focusing (IEF), e.g., capillary technique (cIEF), or capillary zone electrophoresis; amino- or carboxy-terminal sequence analysis; mass spec peptide mapping (e.g., using trypsin / LYS-C) analysis;The antibody can be qualitatively and / or quantitatively assessed in a variety of different ways, including assessing the antibody's biological activity or antigen-binding function;
[0076] In the present invention, the pharmaceutical dosage form may be an isotonic dosage form, and an "isotonic" dosage form has substantially the same osmotic pressure as human blood. An isotonic dosage form generally has an osmotic pressure of about 250-350 mOsm / kg. Isotonicity can be measured, for example, using a water vapor pressure or ice-cooled osmometer.
[0077] In the present invention, "buffering agent" refers to a buffering agent that resists changes in pH by the action of its acid-base conjugate components. In some embodiments, the buffering agent of the present invention adjusts the pH of the dosage form to a pH of about 5.0 to about 7.5, about 5.8 to about 7.0, about 6.0 to about 6.5, or about 6.0 to about 6.3. In one embodiment, examples of buffers that control pH, either alone or in combination, may include acetate, succinate, gluconate, histidine, citrate, phosphate, maleate, cacodylate, 2-[N-morpholino]ethanesulfonic acid (MES), bis(2-hydroxyethyl)iminotris[hydroxymethyl]methane (bis-tris), N-[2-acetamido]-2-iminodiacetic acid (ADA), glycylglycine, or other organic acid buffers.
[0078] In the present invention, the buffer may be a biological buffer, i.e., a buffer known from the prior art for use in biological systems or in their context, but may also be, for example, a mixed buffer containing an inorganic salt and an organic salt.
[0079] In addition, the preferred mixed buffer solution that can be used in the present invention is a biological buffer solution, and may contain an amino acid. The preferred amino acid that can be used in the present invention may be one or more selected from the group consisting of histidine, arginine, and glutamic acid, and preferably contains all of histidine, arginine, and glutamic acid.
[0080] In the present invention, "surfactant" refers to an agent that reduces the surface tension of a liquid. In one embodiment, the surfactant may be a non-ionic surfactant. In a preferred embodiment, the present invention may include both polysorbate 80 and poloxamer 188 as surfactants, but is not limited thereto. Examples of surfactants that may be further included in the present invention include polysorbate (polyoxyethylene sorbitan monolaurate, e.g., polysorbate 20); TRITON® (t-octylphenoxypolyethoxyethanol, a non-ionic detergent, a subsidiary of Union Carbide of The Dow Chemical Company, Middleland, Michigan); sodium dodecyl sulfate; sulfate (SDS); sodium lauryl sulfate; sodium octylglucoside; lauryl, myristyl, linoleyl, or stearyl sulfobetaine; lauryl, myristyl, linoleyl, or stearyl sarcosine; linoleyl, myristyl, or cetyl betaine; lauroamidopropyl, cocamidopropyl, linoleamidopropyl, myristamidopropyl, palmidopropyl, or isostearamidopropyl betaine (e.g., lauroamidopropyl); myristamidopropyl, palmidopropyl, or isostearamidopropyl dimethylamine; sodium methyl cocoyl or disodium methyl oleyl taurate; sorbitan monopalmitate; and the MONAQUAT series (Mona Industries, Inc., Paterson, New Jersey); polyethyl glycol (polyethyl glycol (PEG), polypropylene glycol (PPG) and copolymers of polyoxyethylene and polyoxypropylene glycol (e.g., Pluronics® / Poloxamer, PF68, etc.);
[0081] In one embodiment, the dosage form according to the present invention is sterile and preservative-free. In another embodiment, the dosage form according to the present invention may contain any preservative, and the preservative may be a paraben-free preservative. Parabens are a series of parahydroxybenzoates or esters of parahydroxybenzoic acid that are known to cause cytokine release and stimulation and are associated with various types of cancer. Examples of parabens include methylparaben, ethylparaben, propylparaben, butylparaben, heptylparaben, isobutylparaben, isopropylparaben, benzylparaben, and sodium salts thereof.
[0082] Exemplary paraben-free preservatives include methylphenols (cresols), such as 3-methylphenol (meta-cresol or m-cresol), phenol, phenethyl alcohol, caprylyl glycol, phenoxyethanol, sorbate, potassium sorbate, sodium sorbate, sorbic acid, sodium benzoate, benzoic acid, acemannan, oleuropein, carvacrol, cranberry extract, gluconolactone, green tea extract, Helianthus annuus seed oil, Lactobacillus ferment, Usnea barbata extract, polyaminopropyl biguanide, polyglyceryl-3 palmitate, polyglyceryl-6 caprylate, pomegranate extract, Populus tremuloides leaf extract, resveratrol, Rosmarinus officinalis leaf extract, benzyl alcohol, or any combination thereof.
[0083] The dosage form according to the present invention may further comprise an antioxidant. "Antioxidant" refers to an agent that inhibits the oxidation of other molecules, and examples of antioxidants in the present invention include citrate, lipoic acid, uric acid, glutathione, tocopherol, carotene, lycopene, cysteine, phosphonate compounds such as etidronic acid, desperoxamine, and malate.
[0084] The GX-H9 used in the present invention may be substantially pure (i.e., free of contaminating proteins, etc.) and may be substantially homogeneous. "Substantially pure" GX-H9 means that it comprises at least about 90% by weight, alternatively at least about 95% or 97% by weight, based on the total weight of protein in the pharmaceutical dosage form.
[0085] GX-H9 may include "substantially identical" GX-H9, and the "substantially identical" GX-H9 means that it has a mutation having an equivalent activity to the GX-H9 used in the present invention. The "substantially identical" means, in one embodiment, substantially the same as the GX-H9 amino acid sequence, and the "substantially identical" sequence means a sequence that shows at least 90% homology, most preferably at least 95% homology, 96% or more, 97% or more, 98% or more, or 99% or more homology when the GX-H9 amino acid sequence of the present invention and any other sequence are aligned to maximize the correspondence and the aligned sequence is analyzed using an algorithm commonly used in the art. EXAMPLES
[0086] The present invention will be described in more detail with reference to the following examples. It will be obvious to those skilled in the art that these examples are merely for the purpose of illustrating the present invention and should not be construed as limiting the scope of the present invention. Example 1. Evaluation of the 12-week stability of high-concentration hGH-hyFc formulations 1-1. Summary of preliminary experiment results
[0087] In preliminary experiments on a high-dose formulation of hGH-hyFc (hereafter referred to as "GX-H9"), the aggregation resistance to temperature stress was greater over the pH range of 6.0-6.5 than in other pH ranges. In addition, a higher level of stability was confirmed when using a histidine buffer formulation compared to a phosphate buffer formulation. Furthermore, high stability was obtained when using poloxamer 188 and polysorbate 80 under freeze / thaw and stirring conditions.
[0088] Overall, the SE-HPLC results indicate greater stability at pH 6.1, whereas the RP-UPLC results confirm greater stability in the pH 6.5 formulation containing sodium chloride (data not shown). 1-2. Experimental design
[0089] Below, the stability of a total of five different dosage forms, including a phosphate buffer pH 6.9 dosage form, was evaluated under temperature stress (-70°C, 2-8°C, 25°C, 45°C), freeze / thaw stress, and mild shaking stress. Table 1 shows the dosage form conditions of GX-H9 and the concentration and type of excipients. [Table 1]
[0090] A solution containing GX-H9 was subjected to ultrafiltration (UF) / diafiltration (DF) with each buffer of the formulation conditions (excluding Poloxamer 188) mentioned in Table 1. After measuring pH and conductivity and confirming that the buffer had sufficiently reached equilibrium, the solution was concentrated to the desired concentration, and Poloxamer 188 was added to adjust the concentration to the target concentration.
[0091] GX-H9 samples prepared in each formulation under sterile conditions were filtered through a 0.2 μm polyvinylidene difluoride (PVDF) membrane and then dispensed into pre-sterilized depyrogenated borosilicate vials, which were then capped and crimped with an aluminum seal. Each vial was then placed under stress conditions for stability testing, and samples were extracted at desired time points for stability evaluation (Table 2). Sample aliquots were diluted as necessary for appropriate analysis, and the remaining samples were kept at -70°C for backup testing. Table 2 shows the experimental conditions for the stress conditions and analysis items. [Table 2]
[0092] 1-3. Concentration (A280), turbidity (A330), appearance and pH change
[0093] The concentration, turbidity, visual appearance and pH changes of each formulation were confirmed under stress conditions.
[0094] The concentration of the samples was determined by absorbance measurements at 280 nm using an extinction coefficient of 1.0 mg / mL = 1.04 AU. The final protein concentration was determined corrected for scattering ((A280-A330) / ε 280 = corrected protein concentration).
[0095] The protein concentration, turbidity, appearance and pH of the samples after various stress conditions are shown in Tables 3 and 4. No clear differences were observed in relation to protein concentration, turbidity and pH due to the various stress conditions. No visible particulates were observed in any of the formulations under the various stress conditions. No discernible analytical changes were observed in any of the formulations after 5X freeze / thaw or shaking stress at 2-8°C for 3 days.
[0096] Table 3 shows the concentration, turbidity, appearance and pH changes after temperature stress. [Table 3]
[0097] *C=Clear;T=Turbid;O=Opalescent(translucent);LY=Light Yellow;NC=No Color;NP=No Particles
[0098] Table 4 shows the concentration, turbidity, appearance and pH changes after freeze / thaw and shaking stress. [Table 4]
[0099] *C=Clear;T=Turbid;O=Opalescent(translucent);LY=Light Yellow;NC=No Color;NP=No Particles
[0100] The target concentration of GX-H9 was achieved in all test formulations, which showed scattering levels of <1% for most formulations after preparation. After the stress reaction, the protein concentration, turbidity, appearance and pH of the samples were checked, and no obvious differences were observed in relation to protein concentration, turbidity and pH due to various stress conditions in all test formulations. 1-4.SE-UPLC
[0101] SE-UPLC (also called gel filtration chromatography) separates molecular forms of proteins by size. In this method, high molecular weight species (e.g., aggregates, IgG dimers and oligomers) are eluted in a pre-peak, ahead of the desired (monomeric) IgG species. Low molecular weight species (e.g., degradation products and fragments) are then eluted in a post-peak.
[0102] SE-UPLC was performed using a Waters Acquity UPLC BEH SEC, 200A (4.6x300mm, 1.7μm) and 100mM sodium phosphate, 200mM arginine-HCl, pH 7.0, mobile phase.
[0103] Table 5 shows the SE-UPLC results according to temperature stress. [Table 5]
[0104] Table 6 shows the SE-UPLC results with freeze / thaw and shaking stress. [Table 6]
[0105] The SE-UPLC results for samples stored at -70°C, 2-8°C, 25°C, and 45°C for 12 weeks showed an increase in both high molecular weight (HMW) and low molecular weight (LMW) species, as shown in Tables 5 and 6. Comparison of stability endpoints revealed higher GX-H9 stability at pH 6.1 compared to higher pHs. Furthermore, the 100 mg / mL formulation was more stable than the 150 mg / mL formulation at the same pH 6.1. No discernible trends were observed among all tested formulations when exposed to freeze / thaw and 2-8°C shaking stress, as the resulting data were similar within the t=0 results and assay variability (Tables 5 and 6). 1-5.RP-UPLC
[0106] RP-UPLC separates molecules by differences in hydrophobicity. Separation is dependent on the binding of solutes in the mobile phase to immobilized hydrophobic ligands in the stationary phase. Elution is typically performed by changing the hydrophobicity of the mobile phase using organic solvents in order of increasing molecular hydrophobicity. Solvent gradient separations were performed using an ultra-performance liquid chromatography system (Waters Acquity H-Class UPLC) equipped with a Waters Acquity UPLC Protein BEH300 C4 column (2.1x150mm) with a UV detector (A220) monitoring at 220nm and integrated software (Chromeleon 7.2).
[0107] Table 7 shows the RP-UPLC results due to temperature stress. [Table 7]
[0108] Table 8 shows the RP-UPLC results with freeze / thaw and shaking stress. [Table 8]
[0109] RP-UPLC results for samples stored at -70°C, 2-8°C, 25°C for 12 weeks or 45°C for 3 weeks showed that the pH 6.1 dosage form containing arginine and glutamic acid showed even better stability compared to other higher pH dosage forms. No discernible trends were observed among all tested dosage forms when exposed to freeze / thaw and 2-8°C shaking stress, as the resulting data were similar within the t=0 results and assay variability (Tables 7 and 8). Example 2. Evaluation of hGH-hyFc formulation stability with and without polysorbate 80
[0110] Even in the condition of 10 mM histidine, 0.1% (w / v) poloxamer 188, 55 mM arginine, 55 mM glutamic acid, 90 mM NaCl, pH 6.1, which was selected as the best formulation in Example 1, the formation of insoluble foreign matter and an increase in fine particles were observed. Based on the fact that hGH in GX-H9 has many hydrophobic patches and proteins themselves can form aggregates due to hydrophobic interactions, and that proteins are adsorbed to gas / oil / solid surfaces in the DP container to form a kind of protein film, and the patches created by these being detached can form aggregates as insoluble particles, it was confirmed that the formation of aggregates was significantly improved in a liquid formulation in which not only poloxamer 188 but also polysorbate 80 was added as a surfactant in order to develop a formulation that can prevent the formation of such aggregates.
[0111] Based on the results that the use of poloxamer 188 and polysorbate 80 together inhibits the formation of insoluble foreign matter and fine particles better than the use of poloxamer 188 alone, the concentration of poloxamer 188 was fixed at 0.10% (w / v) in four formulation compositions containing 60 mg / mL hGH-hyFc, and 0.03% (w / v) polysorbate 80 was added. Appearance, fine particle analysis, SE-UPLC, and RP-HPLC (reversed-phase high performance liquid chromatography) analyses were performed on a total of eight formulations. 2-1.Appearance analysis (visual inspection for insoluble foreign matter)
[0112] Various formulations were prepared using hGH-hyFc stock solution (Drug Substance, DS), filtered through a 0.22μm PES filter in a biosafety cabinet, and then dispensed into glass vials at approximately 0.8mL each to prevent the inclusion of external dust, etc. Sample containers stored in the refrigerator (5℃) and at room temperature (25℃) were removed and allowed to warm to room temperature for approximately 30 minutes, after which the outside of the container was thoroughly washed with alcohol on a foreign matter inspection table, and the containers were directly and visually observed to confirm the presence or absence of insoluble foreign matter for 6 months.
[0113] As a result, as shown in Figure 1, when stored in a refrigerator (5°C), no insoluble foreign matter was generated for 6 months when polysorbate 80 was included, but when polysorbate 80 was not included, the generation of insoluble foreign matter was confirmed in a considerable number of samples out of 10 samples after 6 months of refrigeration. In addition, when stored at room temperature (25°C), it was shown that the generation of insoluble foreign matter was generally inhibited when polysorbate 80 was included compared to when it was not included. In particular, Candidate #1 and Candidate #4 did not generate insoluble foreign matter for 3 months. However, when the dosage form did not contain polysorbate 80, the generation of insoluble foreign matter was confirmed in all vials after 6 months of storage at room temperature. 2-2.Sub-visible particle analysis
[0114] Samples for each condition were prepared by taking 1 mL of each sample into a glass vial, and fine particle analysis was performed by an external company (KBIO, Dosage Form Technical Support Team) using Microflow Imaging equipment (MFI 5200, Proteinsimple), MFI View System Software (MVSS) Version 2-R4.1.0.40.4816, and MFI View Analysis Suite (MVAS) Version 1.4.0.
[0115] As a result, as shown in Figure 2, it was observed that after 6 months of refrigerated (5℃) storage, Candidates #1, #2, #4, and #6 containing polysorbate 80 effectively inhibited the formation of fine particles. In relation to the formation of fine particles, it was found that the dosage form not containing polysorbate 80 produced significantly higher levels of fine particles both at refrigerated and room temperature. 2-3.SE-UPLC analysis
[0116] Using an ACQUITY UPLC Protein BEH200 (4.6*300mm) (Waters, 186005226) column, 100mM sodium phosphate (pH7.0), 200mM arginine-HCl, and a mobile phase solution were flowed at a rate of 0.25mL / min, and 10μg of sample for each condition was injected, and the GX-H9 protein peak was confirmed at an absorbance of 280nm.
[0117] As a result, as shown in Figure 3, the purity of Candidates #2, #3, and #5 was confirmed to be excellent after 6 months of storage in a refrigerator (5°C) and at room temperature (25°C). In particular, among the dosage forms containing polysorbate 80, the purity of Candidate #2 was the best. In the case of Candidates #3 and #5, which are dosage forms not containing polysorbate 80, the purity after 6 months of storage in a refrigerator was similar to that of Candidate #2, but it was confirmed that the purity was relatively low after 6 months of storage at room temperature. 2-4.RP-HPLC
[0118] A Proteonavi C4 300 Å 5 μm (Shiseido, 80205) column was used, and 0.05% trifluoroacetic acid (TFA) in water (MPA) and 0.05% trifluoroacetic acid (TFA) in acetonitrile (MPB) mobile phase solutions were run at a rate of 0.5 mL / min under the gradient conditions shown in Table 9. 20 μg of sample was injected, and the peak of the GX-H9 protein was confirmed at an absorbance of 220 nm. [Table 9]
[0119] As a result, as shown in Figure 4, after 6 months of storage in a refrigerator (5°C), the purity was similar among all dosage forms, but after 6 months of storage at room temperature (25°C), Candidate #4 showed relatively the best purity. Example 3. Evaluation of hGH-hyFc formulation stability depending on polysorbate 80 content
[0120] Considering the results of Example 2, the Candidate #2 was determined to be the most suitable formulation. The concentration of polysorbate 80 was varied in the Candidate #2 formulation, and the stability of the hGH-hyFc formulation (appearance analysis, fine particle analysis, SE-UPLC analysis, RP-HPLC analysis) was examined using the same experimental method as in Example 2.
[0121] As a result, the appearance analysis confirmed that a dosage form containing 0.07% (w / v) or more of polysorbate 80 is suitable for storage at room temperature (25°C) for more than 3 months (Figure 5). In addition, fine particle analysis confirmed generally similar fine particles at polysorbate 80 concentrations in the range of 0.03 to 0.15% (w / v) (Figure 6). The SE-UPLC and RP-HPLC results showed that there was no significant difference depending on the polysorbate 80 concentration when stored in a refrigerator (5°C), the SE-UPLC results showed that the purity decreased when the polysorbate 80 concentration was 0.10% (w / v) or more when stored at room temperature, and the RP-HPLC results showed that there was no significant difference in purity depending on the polysorbate 80 concentration when stored at room temperature (Figure 7). Example 4. Evaluation of the stability of high dose hGH-hyFc formulations
[0122] In summary, the above examples were examined to evaluate the stability of the formulation by checking whether insoluble foreign matter was observed through appearance analysis after storage at refrigerated (5°C) and room temperature (25°C) for the following cases: (i) polysorbate 80 was fixed at 0.07% (w / v) and hGH-hyFc was treated with 60, 80, 100, and 120 mg / ml, respectively, and stored in a glass cartridge; (ii) hGH-hyFc was fixed at 120 mg / ml and polysorbate 80 was fixed at 0.03, 0.05, 0.07, 0.10, and 0.15% (w / v), respectively, and stored in a glass cartridge; and (iii) hGH-hyFc was fixed at 60 mg / ml and polysorbate 80 was fixed at 0.07% (w / v), respectively, and stored in a glass vial with preservatives of m-cresol, phenol, or benzyl alcohol. 4-1.Appearance analysis (visual inspection for insoluble foreign matter)
[0123] Various formulations were prepared using hGH-hyFc stock solution (DS), filtered through a 0.22μm PES filter in a biosafety cabinet, and dispensed into glass vials at approximately 1.0mL each to prevent the inclusion of external dust, etc. Sample containers stored in a refrigerator (5℃) and at room temperature (25℃) were removed and allowed to warm to room temperature for approximately 30 minutes, after which the outside of the container was thoroughly washed with alcohol using a foreign matter inspection kit, and the containers were directly and visually observed to confirm the presence or absence of insoluble foreign matter for 6 months.
[0124] As a result, (i) when the concentration of polysorbate 80 was fixed at 0.07% (w / v) and hGH-hyFc was treated with 60 to 100 mg / ml and stored in a glass cartridge, it was confirmed that no insoluble foreign matter was generated for 6 months under refrigeration or at room temperature. (ii) when the concentration of hGH-hyFc was fixed at 120 mg / ml and polysorbate 80 was treated with 0.05 to 0.15% (w / v) and stored in a glass cartridge, it was confirmed that no insoluble foreign matter was generated for 6 months under refrigeration or at room temperature. (iii) when the concentration of hGH-hyFc was fixed at 60 mg / ml and polysorbate 80 was fixed at 0.07% (w / v), treated with 1 mg / mL phenol as a preservative and stored in a glass vial, it was confirmed that no insoluble foreign matter was generated for 6 months under refrigeration or at room temperature (Figure 8). 4-2.SE-UPLC and RP-HPLC Analysis
[0125] Samples from each condition were taken from the glass cartridge or glass vial, diluted to 2 mg / mL with mobile phase buffer and formulation buffer, filtered through a 0.22 μm cellulose acetate centrifuge tube filter, and then placed in an LC vial for SE-UPLC or RP-HPLC analysis.
[0126] SE-UPLC was performed using an ACQUITY UPLC Protein BEH200 (4.6*300mm) (Waters, 186005226) column with 100mM sodium phosphate (pH 7.0), 200mM arginine-HCl, and a mobile phase solution flowed at a rate of 0.25mL / min, and 10μg was injected to confirm the GX-H9 protein peak at an absorbance of 280nm.
[0127] RP-HPLC was performed using a Proteonavi C4 300 Å 5 μm (Shiseido, 80205) column, with a mobile phase solution of 0.05% trifluoroacetic acid (TFA) in water (MPA) and 0.05% trifluoroacetic acid (TFA) in acetonitrile (MPB) at a rate of 0.5 mL / min under the gradient conditions shown in Table 9, and 20 μg of sample was injected to confirm the GX-H9 protein peak at an absorbance of 220 nm.
[0128] As a result, (i) when the concentration of polysorbate 80 was fixed at 0.07% (w / v) and hGH-hyFc was processed to 60-120 mg / mL and stored in a glass cartridge, the purity difference between the hGH-hyFc doses of 60 mg / mL and 120 mg / mL was confirmed to be only 0.5% when stored in a refrigerator (5°C) by SE-UPLC, but the purity difference between the hGH-hyFc doses of 60 mg / mL and 120 mg / mL was confirmed to be 3.6% when stored at room temperature (25°C).In addition, the purity difference between the hGH-hyFc doses of 60 mg / mL and 120 mg / mL when stored at room temperature by RP-HPLC was only 0.8% (Figure 9a).
[0129] (ii) When hGH-hyFc was fixed at 120 mg / ml and treated with polysorbate 80 at concentrations of 0.03 to 0.15% (w / v) and stored in a glass cartridge, there was no difference in purity between polysorbate 80 concentrations of 0.03% (w / v) and 0.15% (w / v) when stored in a refrigerator, and there was also only a slight difference between polysorbate 80 concentrations of 0.03% (w / v) and 0.15% (w / v) when stored at room temperature (Figure 9b).
[0130] (iii) When hGH-hyFc was stored in glass vials at 60 mg / ml and 0.07% (w / v) of polysorbate 80 and preservatives of m-cresol, phenol or benzyl alcohol, respectively, the SE-UPLC results showed that the purity decreased the least in the condition containing 1 mg / ml phenol, and the RP-HPLC results showed no significant difference in purity among all preservatives (Figure 9c).
[0131] As described above, certain parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific techniques are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the true scope of the present invention is defined by the appended claims and their equivalents. [Array catalog pre-text] 1. GX-H9 (hGH-hyFc5) Phe Pro Thr Ile Pro Leu Ser Arg Leu Phe Asp Asn Ala Met Leu Arg Ala His Arg Leu His Gln Leu Ala Phe Asp Thr Tyr Gln Glu Phe Glu Glu Ala Tyr Ile Pro Lys Glu Gln Lys Tyr Ser Phe Leu Gln Asn Pro Gln Thr Ser Leu Cys Phe Ser Glu Ser Ile Pro Thr Pro Ser Asn Arg Glu Glu Thr Gln Gln Lys Ser Asn Leu Glu Leu Leu Arg Ile Ser Leu Leu Leu Ile Gln Ser Trp Leu Glu Pro Val Gln Phe Leu Arg Ser Val Phe Ala Asn Ser Leu Val Tyr Gly Ala Ser Asp Ser Asn Val Tyr Asp Leu Leu Lys Asp Leu Glu Glu Gly Ile Gln Thr Leu Met Gly Arg Leu Glu Asp Gly Ser Pro Arg Thr Gly Gln Ile Phe Lys Gln Thr Tyr Ser Lys Phe Asp Thr Asn Ser His Asn Asp Asp Ala Leu Leu Lys Asn Tyr Gly Leu Leu Tyr Cys Phe Arg Lys Asp Met Asp Lys Val Glu Thr Phe Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Lys Glu Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro Ser His Thr Gln Pro Leu Gly Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys 2. hGH (GenBank: AAA98618.1) (signal ejækjæk svæði) Phe Pro Thr Ile Pro Leu Ser Arg Leu Phe Asp Asn Ala Met Leu Arg Ala His Arg Leu His Gln Leu Ala Phe Asp Thr Tyr Gln Glu Phe Glu Glu Ala Tyr Ile Pro Lys Glu Gln Lys Tyr Ser Phe Leu Gln Asn Pro Gln Thr Ser Leu Cys Phe Ser Glu Ser Ile Pro Thr Pro Ser Asn Arg Glu Glu Thr Gln Gln Lys Ser Asn Leu Glu Leu Leu Arg Ile Ser Leu Leu Leu Ile Gln Ser Trp Leu Glu Pro Val Gln Phe Leu Arg Ser Val Phe Ala Asn Ser Leu Val Tyr Gly Ala Ser Asp Ser Asn Val Tyr Asp Leu Leu Lys Asp Leu Glu Glu Gly Ile Gln Thr Leu Met Gly Arg Leu Glu Asp Gly Ser Pro Arg Thr Gly Gln Ile Phe Lys Gln Thr Tyr Ser Lys Phe Asp Thr Asn Ser His Asn Asp Asp Ala Leu Leu Lys Asn Tyr Gly Leu Leu Tyr Cys Phe Arg Lys Asp Met Asp Lys Val Glu Thr Phe Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe 3. hyFc5 Arg Asn Thr Gly Arg Gly Gly Glu Glu Lys Lys Lys Glu Lys Glu Lys Glu Glu Gln Glu Glu Arg Glu Thr Lys Thr Pro Glu Cys Pro Ser His Thr Gln Pro Leu Gly Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Lys
Claims
1. A liquid pharmaceutical dosage form comprising a human Growth Hormone (hGH) fusion protein, Poloxamer 188 and Polysorbate 80.
2. The dosage form of claim 1, wherein the hGH fusion protein comprises hGH and an immunoglobulin Fc polypeptide.
3. The dosage form of claim 2, wherein the hGH has the amino acid sequence of SEQ ID NO:
2.
4. The dosage form of claim 2, wherein the immunoglobulin Fc polypeptide has the amino acid sequence of SEQ ID NO:
3.
5. The dosage form of claim 1, wherein the hGH fusion protein has the amino acid sequence of SEQ ID NO:
1.
6. 10. The dosage form of claim 1, wherein the dosage form comprises 30 mg / mL to 150 mg / mL of hGH fusion protein.
7. 2. The dosage form of claim 1, wherein the dosage form comprises 0.01% to 0.2% (w / v) poloxamer 188.
8. The dosage form of claim 1, wherein the dosage form comprises 0.01% to 0.2% (w / v) polysorbate 80.
9. 10. The dosage form of claim 1, further comprising one or more excipients selected from the group consisting of histidine, arginine, glutamic acid, and sodium chloride (NaCl).
10. 10. The dosage form of claim 1, further comprising a preservative.
11. 11. The dosage form of claim 10, wherein the preservative is one or more selected from the group consisting of m-cresol, phenol, and benzyl alcohol.
12. The dosage form of claim 11, wherein the preservative is phenol at 1 mg / mL to 2 mg / mL.
13. 10. The dosage form of claim 9, wherein the dosage form comprises 1 mM to 20 mM histidine.
14. 10. The dosage form of claim 9, wherein the dosage form comprises 40 mM to 70 mM arginine.
15. 10. The dosage form of claim 9, wherein the dosage form comprises 40 mM to 70 mM glutamic acid.
16. 10. The dosage form of claim 9, wherein the dosage form comprises 80 mM to 100 mM sodium chloride.
17. 2. The dosage form of claim 1, wherein the dosage form has a pH of 5.5 to 7.
0.
18. 18. The dosage form of claim 17, wherein the dosage form has a pH of 6.0 to 6.
2.
19. 10. The dosage form of claim 1, wherein the dosage form forms less than 1.5% aggregates upon storage for six months under refrigeration.
20. 10. The dosage form of claim 1, wherein the dosage form is for subcutaneous or intramuscular administration.
21. 10. The dosage form of claim 1, wherein the dosage form is stored in a container selected from the group consisting of a bottle, a microtube, a bag, a vial, a cartridge, an injector, and a syringe.
